Emyria Ltd has released a press release.
Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Strong Recruitment for EMD-RX5 Phase 3 Trial
- Emyria Grows MDMA Asset for Neuro & Mental Health Therapy
- Emyria partners with PAX Centre for MDMA-assisted therapy
- Half Yearly Report and Accounts
- Emyria secures clinical-grade MDMA supply for Aust patients
Later from Emyria
- Emyria agrees licensing and commercialisation deal for EMD-RX5
- Emyria to Develop Psilocybin Therapy Care Model
- Emyria Unveils Highest Potency CBD Capsule for FDA Pathway
- Emyria launches new high potency Ultra-Pure CBD capsule
- March 2023 Quarterly Activities Report and Appendix 4C
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria